2021 Fiscal Year Final Research Report
Establishment of new biomarkers for uveitis and development of treatments by transomics analysis
| Project/Area Number |
19K09959
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 56060:Ophthalmology-related
|
|---|
| Research Institution | Tokyo Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2019-04-01 – 2022-03-31
|
| Keywords | 炎症性眼疾患 / ぶどう膜炎 / 人工知能 / 機械学習 |
|---|
| Outline of Final Research Achievements |
Uveitis is one of the major causative diseases of visual impairment, but there are no established biomarkers or treatments for diagnosis and judgment of therapeutic effect. In this study, we make full use of bioinformatics and artificial intelligence to develop inflammatory eye diseases, from the results of general tests that have been performed in insurance clinics to the large amount of data obtained by the latest omics analysis. Created a new biomarker for. In particular, I was able to create new biomarkers for intraocular lymphoma, acute retinal necrosis, and endophthalmitis, which have poor visual acuity.
|
| Free Research Field |
眼科学
|
| Academic Significance and Societal Importance of the Research Achievements |
ベーチェット病やVogt-小柳-原田病などの非感染性ぶどう膜炎には疾患特異的なバイオマーカーが存在しないため、新規バイオマーカーの同定ができれば、早期診断に寄与できるのみならず、治療効果判定や再発の重要な指標となり得る。また、ぶどう膜炎との鑑別にしばしば苦慮する眼内リンパ腫では適切な診断が生命予後を左右するため、生命予後を推定することができるバイオマーカーを創出することができ、今後の個別化治療の基礎になるデータと思われる。
|
